Clinical Trials Logo

Filter by:
NCT ID: NCT05975099 Active, not recruiting - Lyme Disease Clinical Trials

A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age

Start date: July 26, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and immunogenicity in parallel of heptavalent mRNA-1975 and monovalent mRNA-1982 against Lyme disease in healthy adult participants.

NCT ID: NCT05975073 Recruiting - Clinical trials for MTAP-null Solid Tumors

A Phase 1/2 Study of AMG 193 in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors

Start date: July 27, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The main aims of this study are to evaluate the safety and tolerability, and to determine the maximum tolerated dose (MTD) or the recommended combination dose of AMG 193 in combination with IDE397 in adult participants with metastatic or locally advanced MTAP-null solid tumors, and to evaluate the preliminary anti-tumor activity of AMG 193 in combination with IDE397 in adult participants with metastatic or locally advanced MTAP-null Non-Small-Cell Lung Cancer (NSCLC).

NCT ID: NCT05975060 Completed - COVID-19 Clinical Trials

A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.

COVID-19
Start date: September 7, 2023
Phase: Phase 2/Phase 3
Study type: Interventional

This is a Phase 2/3 open-label study to evaluate the safety and immunogenicity of a booster dose of the XBB.1.5 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) recombinant (r) spike (S) protein nanoparticle vaccine (SARS-CoV-2 rS) adjuvanted with Matrix-M™ in previously mRNA COVID-19 vaccinated adult participants ≥18 years of age and baseline SARS CoV-2 seropositive COVID-19 vaccine naïve participants ≥18 years of age.

NCT ID: NCT05975008 Recruiting - Depression Clinical Trials

Pilot Testing a Virtual Mindfulness-Based Intervention to Improve Veterans' Health

RECLAIM
Start date: December 4, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to test a mindfulness-based intervention to reduce depressive symptoms and improve Veterans' community reintegration.

NCT ID: NCT05974865 Completed - Health Literacy Clinical Trials

Amelioration of Literacy Deficits in Prenatal Care

Start date: September 2006
Phase: N/A
Study type: Interventional

The purpose of the study was to develop and evaluate a skill-based, computer intervention designed to facilitate effective prenatal visit communication for women with restricted literacy.

NCT ID: NCT05974852 Active, not recruiting - Clinical trials for Primary Progressive Multiple Sclerosis

Effect of Ocrelizumab on Choroid Plexus Changes in Patients With PPMS

ORATORIO-CP
Start date: October 1, 2023
Phase:
Study type: Observational

The goal of this non-interventional, observational study is to learn if cortical plexus enhancement in patients with primary progressive multiple sclerosis occurs in response to the autoimmune inflammatory process.

NCT ID: NCT05974839 Active, not recruiting - Clinical trials for Primary Progressive Multiple Sclerosis

Effect of Ocrelizumab on Cortical Lesion Accumulation in Patients With PPMS (ORATORIO-Cortical)

ORATORIO-Cort
Start date: October 1, 2023
Phase:
Study type: Observational

The goal of this non-interventional, observational study is to determine whether cortical pathology can be slowed down by use of ocrelizumab.

NCT ID: NCT05974722 Recruiting - GERD Clinical Trials

Mesh Vs Pledgets for Repair of Paraesophageal Hernia

Start date: September 11, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to compare whether the use of Ovitex mesh provides superior reduction in 2-year recurrence compared to pledgeted suture closure (no mesh) for patients undergoing paraesophageal hernia repair at the Cleveland Clinic. The main questions it aims to answer are: - Determine whether there is a difference in 2-year rates of radiographic recurrence with Ovitex versus pledgeted sutures in paraesophageal hernia repair. - Assess patient quality of life (QOL) after paraesophageal hernia repair with pledgets and mesh. A two-tailed research hypothesis will be used to determine whether there are differences between the two arms

NCT ID: NCT05974644 Not yet recruiting - Clinical trials for Amyloidosis, Hereditary

Southeastern ATTR Amyloidosis Consortium: SEATTRAC Family Registry

Start date: September 1, 2024
Phase:
Study type: Observational [Patient Registry]

The study design is a prospective registry including asymptomatic and symptomatic patients who carry a pathogenic TTR mutation. The study will enroll patients who meet the inclusion criteria and none of the exclusion criteria until 1000 patients are enrolled, at which point in time the study investigators will evaluate whether further patient accrual is meaningful.

NCT ID: NCT05974631 Not yet recruiting - Clinical trials for Post-traumatic Stress Disorder (PTSD)

Evaluating Treatments for Suicidal Veterans With PTSD

Start date: June 3, 2024
Phase: N/A
Study type: Interventional

Posttraumatic Stress Disorder (PTSD) is a significant driver of suicide risk among Veterans, but there is a critical knowledge gap about how to treat PTSD among people at elevated risk for suicide. Although evidence-based treatments for PTSD reduce suicide risk, Veterans at high risk for suicidal behavior rarely receive these potentially life-saving treatments. Prior research suggests that a treatment that combines Dialectical Behavior Therapy (DBT) with the DBT Prolonged Exposure protocol (DBT PE) for PTSD improves both PTSD and suicide-related outcomes. This study will evaluate whether DBT + DBT PE improves these outcomes more than Prolonged Exposure plus suicide risk management, the gold standard VA care for this population. The proposed study will also examine factors that make it easier and harder to implement these treatments in VA settings. The results will help to inform treatment guidelines for this high-priority Veteran population.